Dyadic International DYAI

$0.46 +0.03 (6.10%)

Valuation

Market cap
17,211,000
Revenue TTM
$3,090,000
Net income TTM
$-7,360,000
PE ratio
0.00
Forward PE
—
Profit margin
-238.19%
Debt to equity
0.00

Trading

Volume
142,200
Avg volume
190,776
Day's range
$0.44 – $0.49
Shares out
40,064,000
Stochastic %K
62%
Beta
0.96
Analysts
Strong Sell
Price target
$5.50

Price

Company profile

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sect...

Show more

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
561 743 8333
Website
https://www.dyadic.com
Address
1044 North U.S. Highway One, Suite 201, Jupiter, United States

Latest news

Stocktwits

Jbaffs Sep 30, 2:18 PM
$DYAI Is this the worst Stock board in the world? 😂
1 replies
MingChoo Sep 29, 1:38 AM
$DYAI 1$ this week?
0 replies
Jbaffs Sep 28, 7:52 PM
$DYAI Looks like we'll get some contract news soon!
0 replies
focafoca99 Sep 25, 9:58 PM
$DYAI warns it received a Nasdaq deficiency notice for bid price and market value, giving until March 24, 2027 to regain compliance.
1 replies
iAccess_Alpha Sep 25, 2:14 PM
Missed $DYAI live? Access the presentation replay: https://www.webcaster5.com/Webcast/Page/3171/54486 #microcap #smallcap #investing
0 replies
Gandalf01 Sep 20, 10:48 PM
$DYAI More than surprised there's been no discussion or mention on this board from the Q2 earnings call transcript. An analyst asked about cash through the end of the year and CEO Mark E. answered and this is paraphrased go look at it yourself but "we are working with two major suppliers and two pharmaceutical companies to get one of those big chunks of cash that could last several months or several years depending on when it comes in." He went on to say that could have a very very significant impact. But crickets on this board on a very significant statement from the EC. Seems like most people just watch the price and say yay or nay. We really need some people that understand the technology. The one I know is "Golopon", and sorry for messing up your name but you really get it. Let's get this board going with some real research and investigative reporting, and people that understand the technology and the markets. Cheerleaders take a break we don't need you. Glta
2 replies
Gandalf01 Sep 20, 12:39 AM
$DYAI did not see the wrong Sentiment button was pushed on previous post, sorry, definitely bullish here!
0 replies
Gandalf01 Sep 20, 12:19 AM
$DYAI owned this one back in the covid days sold a few years ago at a loss but I've been following it ever since. Buying back in regularly now as I feel it has finally bottomed. I believe the transition to the commercial stage is well along and will continue though the ramp maybe slower than we would like. I think they have great contacts in the biopharma space, outstanding technology with C1, which may produce license revenue, along with enhancing the technology that can then be transplanted on to the industrial bio side. Summary: very comfortable buying back in here. The textbook definition of a bottom in any stock is when everyone has given up and this board pretty much reflects that. So I'm all in. Glta
1 replies